【摘要】 目的 :验证文拉法辛治疗抑郁症的疗效及安全性。方法 :采用多中心、开放性研究 ,6 2例抑郁症、双相情感性精神障碍抑郁相的病人 ,男性 2 4例 ,女性 38例 ,年龄 (4 0±s 12 )a。给予文拉法辛 (114± 4 4 )mg·d- 1,分 2～ 3次口服 ,共用 6wk。采用汉密尔顿抑郁量表 (HAMD )及临床疗效总评量表(CGI)评定疗效 ,采用副反应量表 (TESS)、体检及实验室检查评价安全性。结果 :经治疗后 ,总有效率为 89%。HAMD评分由治疗前的 (2 9± 6 )分 ,下降至 (6± 5)分 (P <0 .0 1)。常见不良反应为口干14% ,兴奋和 (或 )激越 14% ,出汗 10 % ,恶心和 (或 )呕吐 9% ,头痛 8%等。结论 :文拉法辛治疗抑郁症有肯定的疗效 ,不良反应相对少而轻 ,耐受性好。更多还原

【Abstract】 AIM: To test the efficacy and safety of venlafaxine in treating depression. METHODS: In a multicenter open trail, 62 patients [M 24, F 38; age (40± s 12) a] with depression or bipolar affective disorder, depressive phase were given venlafaxine (114±44) mg·d -1 , po , two or three times every day for 6 wk. Therapeutic effects were evaluated with HAMD, CGI; drug safety were evaluated with TESS, physical examination and laboratory data. RESULTS: After treatment the total effective rate of venlafaxine was 89%. Scores of HAMD decreased from 29±6 to 6±5 ( P <0.01). The main adverse reactions were xerostomia (14%), excitation/agitation (14%), sweating (10%), nausea/vomiting (9%) and headache (8%). CONCLUSION: Venlafaxine is effective in treating depression, adverse reactions are relatively mild and well tolerated.更多还原